Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology

Core Insights - Inspira Technologies has developed a modular configuration for its VORTX blood oxygenation delivery technology, which aims to significantly advance extracorporeal oxygenation and transform critical care practices globally [1][4] - The INSPIRA ART system targets the $19 billion mechanical ventilation market, designed to stabilize declining oxygen saturation levels in patients while they are awake and without the use of a ventilator [2][5] - The VORTX system represents a potential paradigm shift in blood oxygenation technology, maintaining a more natural blood flow and reducing harmful effects on blood components, supported by 32 novel patent claims [3] Company Overview - Inspira Technologies is an innovative medical technology company focused on life support and respiratory treatment, with its flagship product, the INSPIRA ART, offering a potential alternative to mechanical ventilators for the 20 million ICU patients with acute respiratory failure annually [5] - The INSPIRA ART is equipped with a HYLA blood sensor for real-time continuous blood monitoring, allowing physicians to make informed decisions without the need for intermittent blood samples [5] - The INSPIRA ART100 system has received FDA 510(k) clearance and Israeli AMAR certification for use in cardiopulmonary bypass procedures [6] Product Development - The modular configuration of the VORTX technology is expected to enhance its versatility and applicability across various medical scenarios [4] - Other products in development include the INSPIRA ART500, Cardi-ART portable modular device, and VORTX Oxygen Delivery System, which have not yet been tested in humans or approved by regulatory entities [7]